Good MorningEquity markets could be volatile on Thursday following NVIDIA's blowout earnings report. The bar was set high, and NVIDIA blew right past it, producing more than 120% YoY revenue growth and widening margin. The bigger news is that demand for its data center and networking products remains strong, leading to better-than-expected guidance. The problem is that as high as the bar was set, the market hoped for another blowout and moved lower on the news. In this environment, NVIDIA could remain range-bound for the foreseeable future.
Volatility could persist through the end of the week. The July read of the PCE price index is due on Friday ahead of a three-day weekend and is expected to accelerate. Accelerating inflation is contrary to the idea of falling interest rates and will be a negative for stocks. As it is, the market is banking on a rate cut in September and three by year's end, which may be too many too soon. Featured: Most of your net worth in one stock? (Ad) 
|
Consumer Discretionary | |
MGM Resorts International (NYSE: MGM) shares have struggled to exit a trading range entered in 2021 and recently moved to retest the lows, providing an opportunity the insiders took advantage of. The low was triggered by fear of recession caused by weaker-than-expected labor market data, which is ... Read the Full Story |
|
From Our Partners | | In June 2024, a 50-year arrangement tying Saudi oil to the U.S. dollar quietly expired. Garrett Goggin, CFA, CMT - whose gold portfolio has climbed more than 1,200% over the past two years, including a 1,023% gain in G2 Goldfields - believes this is the biggest opportunity of his 31-year career.
Central banks are buying gold bullion at a pace not seen since 1950. The last time the monetary system shifted this dramatically, in 1971, gold surged from $35 to $850. Goggin has identified four specific positions for the next leg of this rally, plus two bonus opportunities for readers. | | Read the free briefing and see all four positions now |
|
Retail/Wholesale | |
When investors think of commodities and their long-term demand cycles, gold and silver often come to mind as investments that can take advantage of the market's long-term upside. However, the answer to aligning a portfolio with a long-term winning commodity involves figuring out which leading econ... Read the Full Story |
|
Technology | |
Earnings results from the Q2 reporting cycle are mixed. Some are good, and some are bad. The takeaway is that some are good, and the analysts reward those companies with upgrades and price target revisions to increase their share prices. That is the focus of this article: the three stocks the most... Read the Full Story |
|
From Our Partners | | Elon Musk's new banking platform is paying up to 15 times the national average interest rate while insuring deposits up to $250,000 - just like a traditional bank. It moved $1 billion in a matter of days.
Senior Investment Analyst Luke Lango says this is the first sign of a much bigger financial shift - one with real profit potential for investors who position early. JPMorgan CEO Jamie Dimon has already warned banks to be 'scared' of exactly this kind of disruption. | | See how it works and how to position yourself for the opportunity |
|
Retail/Wholesale | |
Kohl's Corporation (NYSE: KSS) finds itself navigating choppy waters in the turbulent sea of the retail sector. The renowned omnichannel retailer, known for its value-driven offerings and loyal customer base, recently released its second-quarter fiscal year 2024 earnings report. Kohl’s earni... Read the Full Story |
|
Retail/Wholesale | |
Chewy’s (NYSE: CHWY) stock price has struggled since the peaks set in 2020 because it could not sustain the wicked-hot growth pace driven by pandemic spending and stimulus measures. Today’s takeaway is that the market for Chewy stock has normalized, and its business turned a corner i... Read the Full Story |
|
From Our Partners | | Gold has more than doubled since April 2024 - but according to Ross Givens, Director of Research at Traders Agency, history says this cycle is still in its early stages.
During the last gold supercycle in the 2000s, one overlooked leveraged asset returned 846%, 1,668%, 1,847%, and 1,915%. The same conditions that drove those gains are now back in place. | | See the asset positioned to multiply gold's move multiple times over |
|
Finance | |
Last Friday, Federal Reserve Chair Jerome Powell provided the most unambiguous indication yet that the central bank is preparing to lower historically high interest rates in September. While he didn't specify the exact amount of the rate cut, most experts anticipate a quarter-point reduction. Powe... Read the Full Story |
|
Technology | |
AI is big business, and Ambarella (NASDAQ: AMBA) will benefit from it over the next decade, probably longer. While attention has been fixed on infrastructure names like NVIDIA (NASDAQ: NVDA), Microsoft (NASDAQ: MSFT), and Oracle (NYSE: ORCL), the time has come to pay attention to the next wave of ... Read the Full Story |
|
Basic Materials | |
Over an economic cycle, it is no secret that a few asset classes tend to outperform the rest under the right fundamental conditions, something that investors can get behind to get their capital on what could be the winning side of history. With business activity slowing down for 21 months, accordi... Read the Full Story |
|
Medical | |
During times of market volatility, it’s always good for long-term investors to take a breath and zoom out. That doesn’t mean getting out of the markets as fast as possible. Instead, it means looking back at the past performance of the stocks they own or those on their watchlist(s).
... Read the Full Story |
|
Markets | |
Investors might begin to question whether this surge has gone too far or too fast as the utilities sector continues its impressive climb. With the sector ETF's Utilities Select Sector SPDR (NYSE: XLU) recent outperformance, some might be wondering if it's now overbought and due for a pullback in... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. | | View Today's Stock Pick |
|
